Drug Resistance

Lung Resistance Protein Predictive of Response in Ovarian Cancer

Published in Gene Therapy Weekly, September 4th, 1995

A newly described protein, the lung resistance protein (Lrp), which is also called the p110 major vault protein, is indicative of response to chemotherapy and long-term prognosis in advanced ovarian carcinoma.

Roughly 75% of the women diagnosed with ovarian cancer present with surgically incurable advanced disease. Chemotherapy after debulking surgery has increased the 5-year survival rate to 10-20 percent. Drug-resistant cancer cells that exist prior to or develop after treatment are likely to be responsible for the high rate of chemotherapy failure. However, previously discovered drug-resistance mechanisms have failed to be indicative of chemotherapy response in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-09-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry